Lapo Alinari

5.2k total citations
115 papers, 2.8k citations indexed

About

Lapo Alinari is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Lapo Alinari has authored 115 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 52 papers in Oncology and 34 papers in Genetics. Recurrent topics in Lapo Alinari's work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (34 papers) and Viral-associated cancers and disorders (19 papers). Lapo Alinari is often cited by papers focused on Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (34 papers) and Viral-associated cancers and disorders (19 papers). Lapo Alinari collaborates with scholars based in United States, Italy and Canada. Lapo Alinari's co-authors include Pier Luigi Zinzani, Monica Tani, Vittorio Stefoni, Robert A. Baiocchi, Michele Baccarani, Enrica Marchi, Gerardo Musuraca, Stefano Pileri, Paolo Castellucci and Mariapaola Fina and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Lapo Alinari

108 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lapo Alinari United States 30 1.7k 793 623 518 491 115 2.8k
Enrico Derenzini Italy 25 1.2k 0.7× 766 1.0× 405 0.7× 370 0.7× 344 0.7× 99 1.9k
Ingrid Simonitsch‐Klupp Austria 29 1.1k 0.6× 586 0.7× 356 0.6× 816 1.6× 376 0.8× 93 2.4k
Amanda F. Cashen United States 29 1.4k 0.8× 1.0k 1.3× 629 1.0× 445 0.9× 549 1.1× 121 2.9k
Enrica Marchi United States 21 1.2k 0.7× 558 0.7× 430 0.7× 458 0.9× 248 0.5× 88 1.7k
Pauline Brice France 23 2.3k 1.4× 1.4k 1.7× 208 0.3× 474 0.9× 546 1.1× 75 3.1k
Jacques Bosq France 31 1.1k 0.7× 1.2k 1.5× 482 0.8× 620 1.2× 245 0.5× 74 2.5k
Rémy Gressin France 26 1.7k 1.0× 1.2k 1.5× 379 0.6× 561 1.1× 880 1.8× 109 2.5k
Achiel Van Hoof Belgium 18 1.9k 1.2× 1.3k 1.7× 375 0.6× 339 0.7× 918 1.9× 33 2.6k
Catherine Spier United States 30 1.8k 1.1× 2.0k 2.5× 857 1.4× 583 1.1× 671 1.4× 73 3.6k
R. Gregory Bociek United States 27 1.7k 1.0× 1.3k 1.6× 690 1.1× 420 0.8× 927 1.9× 119 2.9k

Countries citing papers authored by Lapo Alinari

Since Specialization
Citations

This map shows the geographic impact of Lapo Alinari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lapo Alinari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lapo Alinari more than expected).

Fields of papers citing papers by Lapo Alinari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lapo Alinari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lapo Alinari. The network helps show where Lapo Alinari may publish in the future.

Co-authorship network of co-authors of Lapo Alinari

This figure shows the co-authorship network connecting the top 25 collaborators of Lapo Alinari. A scholar is included among the top collaborators of Lapo Alinari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lapo Alinari. Lapo Alinari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations
2.
Tsyba, Liudmyla, Neeraj Jain, Lalit Sehgal, et al.. (2025). Targeting the DNA damage response through TBL1X in mantle cell lymphoma. Blood Advances. 9(8). 2006–2018. 1 indexed citations
3.
Lee, Heng‐Huan, Violetta V. Leshchenko, Ravi Prakash Shukla, et al.. (2025). SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Advances. 9(24). 6267–6278.
4.
Lee, Heng‐Huan, Ravi Prakash Shukla, Violetta V. Leshchenko, et al.. (2024). Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance. Blood. 144(Supplement 1). 1402–1402. 1 indexed citations
5.
Alinari, Lapo, et al.. (2024). Design, Synthesis, and Biological Evaluation of Selective TBL1X Degraders. ACS Medicinal Chemistry Letters. 15(10). 1699–1707.
6.
Liu, Tingting, Tycel Phillips, Geoffrey Shouse, et al.. (2023). T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. Molecular Cancer Therapeutics. 22(9). 1040–1051. 8 indexed citations
7.
8.
Xu‐Monette, Zijun Y., Krysta M. Coyle, Laura K. Hilton, et al.. (2023). Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 37(10). 2094–2106. 4 indexed citations
9.
Chan, Wing Keung, Jessica Williams, Zehua Bian, et al.. (2023). A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Experimental Hematology and Oncology. 12(1). 79–79. 9 indexed citations
10.
Youssef, Youssef, et al.. (2022). TBL1X: At the crossroads of transcriptional and posttranscriptional regulation. Experimental Hematology. 116. 18–25. 13 indexed citations
11.
12.
Harrington, Bonnie K., Esther F. Wheeler, Youssef Youssef, et al.. (2019). Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia & lymphoma. 60(10). 2498–2507. 23 indexed citations
13.
Lanuti, Paola, Valeria Bertagnolo, Laura Pierdomenico, et al.. (2009). Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Research. 19(9). 1079–1089. 26 indexed citations
14.
Zinzani, Pier Luigi, Monica Tani, Gerardo Musuraca, et al.. (2008). A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Annals of Oncology. 19(4). 769–773. 58 indexed citations
15.
Alinari, Lapo, Rosa Lapalombella, Leslie A. Andritsos, et al.. (2007). Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 26(25). 3644–3653. 84 indexed citations
16.
Zinzani, Pier Luigi, Pietro Quaglino, Nicola Pimpinelli, et al.. (2006). Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. Journal of Clinical Oncology. 24(9). 1376–1382. 143 indexed citations
17.
Zinzani, Pier Luigi, Monica Tani, Stefano Fanti, et al.. (2006). Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Annals of Oncology. 17(8). 1296–1300. 106 indexed citations
18.
Castellucci, Paolo, Pier Luigi Zinzani, Cristina Nanni, et al.. (2004). Short Communication: 18 F-FDG PET Early After Radiotherapy in Lymphoma Patients. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 606–612. 18 indexed citations
19.
Zinzani, Pier Luigi, Giuseppe Battista, Monica Tani, et al.. (2004). Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. British Journal of Cancer. 91(5). 850–854. 81 indexed citations
20.
Zinzani, Pier Luigi, Monica Tani, Annalisa Gabriele, et al.. (2003). Extranodal Marginal Zone B-cell Lymphoma of MALT-type of the Lung: Single-center Experience with 12 Patients. Leukemia & lymphoma. 44(5). 821–824. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrico Derenzini Breakdown of academic impact, for papers by Ingrid Simonitsch‐Klupp Breakdown of academic impact, for papers by Amanda F. Cashen Breakdown of academic impact, for papers by Enrica Marchi Breakdown of academic impact, for papers by Pauline Brice Breakdown of academic impact, for papers by Jacques Bosq Breakdown of academic impact, for papers by Rémy Gressin Breakdown of academic impact, for papers by Achiel Van Hoof Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by R. Gregory Bociek
Rankless by CCL
2026